This is a preview of subscription content, log in via an institution to check access.
Reference
EMA. PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids. Internet Document : 4 Sep 2020. Available from: URL: https://www.ema.europa.eu/en/news/prac-recommends-revoking-marketing-authorisation-ulipristal-acetate-uterine-fibroids
Rights and permissions
About this article
Cite this article
Ulipristal for uterine fibroids should not be marketed in the EU, says EMA. Reactions Weekly 1821, 6 (2020). https://doi.org/10.1007/s40278-020-83126-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-83126-8